Additional information
| Additional |
Information |
| Market: |
TSX |
| Sector: |
Pharmaceuticals |
| Epic: |
TSX:SBS |
| News: |
Latest news |
| Web Site: |
SemBioSys Genetics |
| Other Articles: |
|
Wednesday March 17, 09:01SmartFocus, Amphion Innovations and National Milk Records confirmed for March 18 Forum
The presentations will start at 6:00pm and finish at approx 7:30pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception.
FULL ARTICLE ►
Thursday March 18, 12:26Healthcare & Biotech companies to present at "Ultimate Healthcare & Biotechnology Event 2010”
We have a cracking line-up for March 24, as we return to Healthcare & Biotech sector at our One2One Investor Forum. Seats are limited, to avoid disappointment, register now.
FULL ARTICLE ►
Monday March 15, 09:01China's growth boosting commodity prices
The latest economic figures from China have put pressure on the
dollar and boosted a number of high-yielding currencies, including the
Australian dollar and the South African rand.
FULL ARTICLE ►
SemBioSys Genetics Inc. is a plant biotechnology company with a technology that enables production of high-value pharmaceutical and non-pharmaceutical products in an affordable and sustainable manner.
SemBioSys gets US$2.5 mln from option agreement with MannKind for plant-produced insulin
Biotechnology group SemBioSys Genetics Inc said it has received US$ 2.5 million from MannKind Corp as payment for the option agreement and issuance of 2.4 million SemBioSys unit, as announced on December 24, 2008.
The transaction gives MannKind the option to the license rights to SemBioSys' proprietary plant-produced recombinant human insulin for use primarily in MannKind's ultra-rapid acting insulin, AFRESA.
The units were issued at a price US$0.83 and consist of one common share of SemBioSys and one-tenth of one common share purchase warrant of SemBioSys. Each whole warrant entitles MannKind to purchase one additional common share of SemBioSys at an exercise price of CDN$6.00 for a period of 36 months from the effective date of the option. The option period for the license rights ends on March 31, 2009.
Calgary, Alberta-based SemBioSys develops protein-based pharmaceuticals using its proprietary protein production technology. This technology enables the production of therapeutic proteins in plant seeds by genetically enhancing the safflower plant. SemBioSys' lead pharmaceutical candidates are recombinant human insulin.
Register here to be notified of future SemBioSys Genetics articles.
Investors interested in SemBioSys Genetics recently viewed
No investment advice
The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
